Pinnacle Associates LTD Amgen Inc Transaction History

Pinnacle Associates LTD

  • $6.17 Billion
  • Q1 2024

A detailed history of Pinnacle Associates LTD transactions in Amgen Inc stock. As of the latest transaction made, Pinnacle Associates LTD holds 63,478 shares of AMGN stock, worth $19.8 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
63,478
Previous 56,555 12.24%
Holding current value
$19.8 Million
Previous $16.3 Million 10.81%
% of portfolio
0.29%
Previous 0.28%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 26, 2024
BUY
$268.87 - $324.56 $1.86 Million - $2.25 Million
6,923 Added 12.24%
63,478 $18 Million
Q4 2023

Jan 19, 2024
SELL
$255.7 - $288.46 $154,698 - $174,518
-605 Reduced 1.06%
56,555 $16.3 Million
Q3 2023

Oct 23, 2023
SELL
$218.65 - $271.46 $981,519 - $1.22 Million
-4,489 Reduced 7.28%
57,160 $15.4 Million
Q2 2023

Jul 26, 2023
BUY
$214.27 - $253.37 $403,256 - $476,842
1,882 Added 3.15%
61,649 $13.7 Million
Q1 2023

May 04, 2023
BUY
$225.79 - $275.2 $1.18 Million - $1.44 Million
5,243 Added 9.62%
59,767 $14.4 Million
Q4 2022

Jan 31, 2023
SELL
$229.03 - $291.01 $21,070 - $26,772
-92 Reduced 0.17%
54,524 $14.3 Million
Q4 2022

Jan 25, 2023
SELL
$229.03 - $291.01 $1.22 Million - $1.54 Million
-5,305 Reduced 8.85%
54,616 $0
Q3 2022

Oct 31, 2022
SELL
$224.46 - $253.15 $184,506 - $208,089
-822 Reduced 1.35%
59,921 $13.5 Million
Q2 2022

Aug 02, 2022
SELL
$230.71 - $256.74 $330,838 - $368,165
-1,434 Reduced 2.31%
60,743 $14.8 Million
Q1 2022

May 05, 2022
BUY
$219.27 - $242.57 $107,003 - $118,374
488 Added 0.79%
62,177 $15 Million
Q4 2021

Feb 02, 2022
SELL
$198.88 - $227.6 $265,107 - $303,390
-1,333 Reduced 2.12%
61,689 $13.9 Million
Q3 2021

Oct 19, 2021
SELL
$212.27 - $248.7 $542,349 - $635,428
-2,555 Reduced 3.9%
63,022 $13.4 Million
Q2 2021

Aug 02, 2021
BUY
$233.58 - $259.14 $243,390 - $270,023
1,042 Added 1.61%
65,577 $16 Million
Q1 2021

May 12, 2021
BUY
$221.91 - $258.6 $85,435 - $99,561
385 Added 0.6%
64,535 $16.1 Million
Q4 2020

Jan 26, 2021
SELL
$216.38 - $257.67 $1.34 Million - $1.59 Million
-6,181 Reduced 8.79%
64,150 $14.7 Million
Q3 2020

Oct 23, 2020
SELL
$234.65 - $260.95 $51,857 - $57,669
-221 Reduced 0.31%
70,331 $17.9 Million
Q2 2020

Aug 14, 2020
BUY
$197.81 - $242.74 $196,623 - $241,283
994 Added 1.43%
70,552 $16.6 Million
Q1 2020

May 13, 2020
BUY
$182.24 - $241.7 $162,375 - $215,354
891 Added 1.3%
69,558 $14.1 Million
Q4 2019

Feb 03, 2020
SELL
$189.21 - $243.2 $1.09 Million - $1.4 Million
-5,775 Reduced 7.76%
68,667 $16.6 Million
Q3 2019

Nov 08, 2019
BUY
$174.11 - $208.62 $563,594 - $675,302
3,237 Added 4.55%
74,442 $14.4 Million
Q2 2019

Aug 05, 2019
BUY
$166.7 - $195.41 $623,124 - $730,442
3,738 Added 5.54%
71,205 $13.1 Million
Q1 2019

May 10, 2019
SELL
$180.87 - $203.88 $635,938 - $716,842
-3,516 Reduced 4.95%
67,467 $12.8 Million
Q4 2018

Feb 05, 2019
BUY
$178.4 - $208.25 $296,857 - $346,528
1,664 Added 2.4%
70,983 $13.8 Million
Q3 2018

Nov 13, 2018
SELL
$185.29 - $208.89 $85,418 - $96,298
-461 Reduced 0.66%
69,319 $14.4 Million
Q2 2018

Aug 08, 2018
SELL
$166.05 - $186.51 $316,657 - $355,674
-1,907 Reduced 2.66%
69,780 $12.9 Million
Q1 2018

May 11, 2018
SELL
$169.43 - $198.0 $402,565 - $470,448
-2,376 Reduced 3.21%
71,687 $12.2 Million
Q4 2017

Feb 12, 2018
SELL
$168.79 - $188.59 $289,137 - $323,054
-1,713 Reduced 2.26%
74,063 $12.9 Million
Q3 2017

Nov 13, 2017
SELL
$167.29 - $191.0 $286,902 - $327,565
-1,715 Reduced 2.21%
75,776 $14.1 Million
Q2 2017

Aug 09, 2017
BUY
N/A
77,491
77,491 $13.3 Million

Others Institutions Holding AMGN

# of Institutions
2,930
Shares Held
401M
Call Options Held
6.59M
Put Options Held
6.6M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $167B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Pinnacle Associates LTD Portfolio

Follow Pinnacle Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email